SaaS Metrics
Drug Development Progress
Plasma Levels
AI Synthesis & Market Narrative
Pharmaceutical companies are actively progressing Phase 1 clinical trials for novel therapies targeting weight loss, respiratory diseases, and metabolic disorders. These trials critically rely on monitoring plasma levels to assess drug safety, tolerability, and bioavailability.
Correlated Linguistic Patterns
["Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019"
"pharmacokinetics of VK3019"
"Phase 1 clinical trial of KIT2014"
"robust bioavailability and sustained increases in calcium"
"oral peptide"]
Driving Media Context
Brain–spleen axis regulates learned fear
A multisynaptic pathway from the piriform cortex to the spleen drives learned fear avoidance behaviour in mice.
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019 Potential to further expand Viking's treatment options for weight...
Kither Biotech successfully completes Phase 1 clinical trial of KIT2014, a novel inhaled peptide therapy for respiratory diseases
Kither Biotech announces the successful completion of its Phase 1 clinical study of KIT2014 in healthy participants. ...
The Skin Microbiome Secret to Sun Protection and Radiant Health
Aside from the microbiome living in your gut, did you know that your body is also home to other microbiomes, too? One example that doesn’t get enough time in...
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across...
Clinical Trial Finds Tomato-Soy Juice Reduces Inflammatory Markers in Adults with Obesity
A four-week clinical trial published in the journal Molecular Nutrition & Food Research has found that daily consumption of a tomato-soy juice significantly ...
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
Experienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval SAN DIEGO, June 11, 2026 /...
Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success
Artelo’s lead medicinal chemist reveals findings at the Royal Society of Chemistry-BMCS/DMDG Medicinal Chemistry Conference in London Artelo’s lead medicinal...
The Fast-Track Path to Clearing Vegetable Oils from Your Skin
Linoleic acid (LA) is the most abundant fat in the modern diet, not because your body requires it in large amounts, but because it's the primary omega-6 poly...
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
BRIDGEWATER, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced new positive in...